Bayer has revealed promising new data on finerenone, highlighting its effectiveness in reducing both cardiovascular death and total heart failure events
Finerenone has successfully met the primary endpoint in the Phase III FINEARTS-HF study, demonstrating a significant reduction in cardiovascular death and total heart failure events compared to placebo. This achievement marks a significant milestone for patients with heart failure (HF) with mildly reduced or preserved ejection fraction (LVEF ≥40%), a group with limited approved treatment options.
Study Details and Results
The FINEARTS-HF study evaluated the efficacy and safety of finerenone, marketed as Kerendia, in patients with symptomatic HF (New York Heart Association class II-IV) and a LVEF of 40% or higher. Approximately 6,000 patients were randomized to receive either finerenone or a placebo, alongside usual therapy, for up to 42 months. The study focused on reducing cardiovascular death and total HF events, which include hospitalizations for HF or urgent HF visits.
The results indicated that finerenone significantly lowered the composite endpoint of cardiovascular death and total HF events. The drug was well-tolerated, aligning with its known safety profile.
FINEARTS-HF Study Overview
The FINEARTS-HF study was a randomized, double-blind, placebo-controlled, multicenter trial. It aimed to prevent cardiovascular death and HF events in patients with symptomatic HF and a LVEF of 40% or more. The primary endpoint was the composite of cardiovascular death and total HF events.
Heart Failure with Preserved Ejection Fraction
Heart failure is a chronic condition where the heart's ability to pump blood efficiently diminishes over time. It affects over 60 million people globally, with about half of these patients having HF with a LVEF of 40% or higher. This subset of HF is associated with multiple comorbidities, making management particularly challenging. Current trends suggest that this patient population will soon comprise the majority of HF hospitalizations.
About Finerenone
Finerenone is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist. It targets the MR and renin-angiotensin-aldosterone system (RAAS) overactivation, addressing key aspects of HF with LVEF ≥40%, such as progressive fibrosis. The drug has already shown cardiovascular benefits in other indications and now demonstrates promise for patients with HF and preserved ejection fraction.
Comentários